What are U.S. Agent fees for QMSR transition support?

Foreign medical device manufacturers preparing for the Quality Management System Regulation (QMSR) compliance deadline often look to their U.S. Agent for transition support. While the basic responsibilities of a U.S. Agent are defined, providing QMSR transition support represents an expanded, consultative role. What factors typically determine the scope and cost model for these services? For instance, how does the service offering differ between a U.S. Agent providing high-level strategic guidance versus one offering hands-on implementation? The complexity of a manufacturer's operations—such as the number of device classes, manufacturing sites, and the maturity of their existing ISO 13485-based quality system—is a significant variable. A key consideration is whether the support is structured as a fixed-fee project for specific deliverables, like a gap analysis and remediation plan, or as an hourly retainer for ongoing advisory support. Furthermore, how do different pricing models account for activities such as revising quality manuals and standard operating procedures (SOPs), conducting staff training on the new requirements, and performing mock audits to prepare for FDA inspections? Understanding the breakdown of these potential services—from initial assessment to full implementation and verification—is crucial for foreign manufacturers to budget appropriately and select a U.S. Agent partner whose capabilities match their specific transition needs without receiving case-specific advice. --- *This Q&A was AI-assisted and reviewed for accuracy by Lo H. Khamis.*